Amgen announced Amjevita, a biosimilar to Humira, is now available in the United States. Amjevita was the first biosimilar to Humira approved by the FDA, in 2016.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on AMGN:
- AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS
- Amgen lays off 300 employees, or 1.2% of workforce, Reuters reports
- Can Amgen (AMGN) Q4 Earnings Beat Street Expectations?
- Warren writes FTC over concerns of two pharma deals, Reuters reports
- Amgen price target cut at Piper on lower Otezla estimates